Business Wire11.08.21
QIAGEN and BD have reached a settlement in the patent infringement lawsuit related to QIAGEN’s NeuMoDx 96 and NeuMoDx 288 clinical PCR systems that QIAGEN acquired from NeuMoDx Inc. in 2020.
Under terms of the agreement, all pending patent and non-patent claims have been resolved between BD and QIAGEN and the co-defendants who were former officers of NeuMoDx in the lawsuit in the U.S. District Court for the District of Delaware. BD will receive a one-time, lump-sum payment of $53 million. The settlement includes general releases of all parties with no admissions of wrongdoing.
This agreement does not affect QIAGEN’s outlook for net sales and adjusted earnings per share (EPS) for the fourth quarter and full-year 2021.
Under terms of the agreement, all pending patent and non-patent claims have been resolved between BD and QIAGEN and the co-defendants who were former officers of NeuMoDx in the lawsuit in the U.S. District Court for the District of Delaware. BD will receive a one-time, lump-sum payment of $53 million. The settlement includes general releases of all parties with no admissions of wrongdoing.
This agreement does not affect QIAGEN’s outlook for net sales and adjusted earnings per share (EPS) for the fourth quarter and full-year 2021.